Biotech

All Articles

Zephyrm finds Hong Kong IPO to cash phase 3 cell treatment trials

.Zephyrm Bioscience is gusting towards the Hong Kong stock market, submission (PDF) for an IPO to ba...

Frazier Lifestyle Sciences collects $630M for small, mid-cap biotechs

.Frazier Life Sciences has sourced an additionally $630 thousand for its fund focused on small and m...

GigaGen achieves approximately $135M BARDA money to beat botulism

.Antibody enthusiast GigaGen, a subsidiary of Spanish biopharma Grifols, is ramping up its own techn...

GPCR company Septerna apply for IPO on stamina of preclinical information

.Septerna is about to discover exactly how a biotech without "any kind of purposeful medical records...

Kurma shuts first $154M loot for greatest biotech fund as yet

.International VC agency Kurma Partners has unveiled its most recent biotech fund, along with 140 th...

Prothena advertises one officer while an additional keeps-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our roundup of significant leadership hirings, firings and r...

Editas cashes in on Tip Cas9 licensing civil liberties for $57M

.Against the scenery of a Cas9 license struggle that refuses to die, Editas Medicine is moneying in ...

Ultragenyx fine-tunes genetics treatment dosing to call up efficiency

.A minority of patients taking Ultragenyx Drug's Wilson health condition gene therapy UX701 have com...

Biopharma unemployment rate maintains in Q3: Strong Biotech review

.As summer heat counts on cool down winds, wishes that this year would take prevalent sector comfort...

J &amp J goes down stage 2 dengue prospect in most current switch coming from injections

.Johnson &amp Johnson's deprioritization of its infectious condition pipeline has actually asserted ...